Dr. Arevitalize vs TeleCareSpot
Two GLP-1 desks, one scoreboard. We put Dr. Arevitalize and TeleCareSpot head-to-head on the published Brief Score — the same six factors, scored the same way.
Dr. Arevitalize
TeleCareSpot
The verdict
TeleCareSpot takes this head-to-head.
TeleCareSpot scores 85 to 68 on our six-factor Brief Score — A nationwide desk with an oral option — full-formulary, but priced at the premium end.
That doesn't make Dr. Arevitalize a bad call — it's best for readers who want compounded semaglutide & tirzepatide in both injection and oral-capsule forms. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Dr. Arevitalize | TeleCareSpot | |
|---|---|---|
| Brief Score | 68/100 (C) | 85/100 (B) |
| Semaglutide | From $319/mo (compounded) | $299/mo |
| Tirzepatide | From $359/mo (compounded) | $399/mo |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
| On the tracker | Newnew to the tracker, no prior reading | Stableprice stable |
Dr. Arevitalize: New to the tracker on 1 August 2026. The published line reads From $319/mo (compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
TeleCareSpot: $299 sema / $399 tirz nationwide, with an oral route.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Keep comparing
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.